# Re-evaluation Task: HN2-007

## Context
- **Case ID**: HN2-007
- **Cancer type**: Floor of Mouth Squamous Cell Carcinoma
- **Stage**: T3N1M0 (Stage III) — mandible periosteal invasion
- **Molecular profile**: PD-L1 CPS 15, TP53 mutation, PIK3CA mutation
- **Report file**: experiment_reports\HN2-007_report.json
- **Current score**: 87/100
- **Gap analysis (local GPU)**: The most critical gaps in the cancer research report HN2-007 are the lack of data on Pembrolizumab Monotherapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Palbociclib + Cetuximab for CDK4/6 Inhibition in combination with anti-EGFR/TGF inhibition, which will improve the score by providing more comprehensive information on effective treatment strategies for these specific patient populations. Filling these gaps will enable researchers to better understand the efficacy of these treatments and inform clinical decision-making, ultimately leading to improved patient outcomes.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  14/25  |  56.0% |
| clinical_relevance                  |   9/10  |  90.0% |
| rating_calibration                  |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (56.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\HN2-007_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Floor of Mouth Squamous Cell Carcinoma",
    "stage": "T3N1M0 (Stage III) — mandible periosteal invasion",
    "molecular_profile": [
      "PD-L1 CPS 15",
      "TP53 mutation",
      "PIK3CA mutation"
    ],
    "patient_context": "45-year-old male, heavy smoker and heavy alcohol use, hepatic steatosis (fatty liver disease)",
    "special_considerations": [
      "Mandible periosteal invasion requires marginal vs segmental mandibulectomy decision",
      "Free flap reconstruction required if segmental mandibulectomy performed",
      "PD-L1 CPS 15 qualifies for perioperative pembrolizumab (KEYNOTE-689)",
      "Liver steatosis may affect 5-FU and methotrexate metabolism but cisplatin is renally cleared",
      "Tobacco and alcohol cessation is critical — 3.7x higher odds of complete response in quitters"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Perioperative Pembrolizumab + Surgery + Adjuvant CRT (KEYNOTE-689 Regimen)",
      "category": "Immunotherapy — Perioperative",
      "composite_rating": 8.7,
      "rating_breakdown": {
        "evidence_level": {
          "score": 10,
          "rationale": "Phase 3 RCT (KEYNOTE-689, N=714) published in NEJM 2025; FDA approved June 2025 for PD-L1 CPS>=1 LA-HNSCC"
        },
        "survival_benefit": {
          "score": 8,
          "rationale": "EFS HR 0.70 (CPS>=1); median EFS 59.7 vs 29.6 months; 36-month EFS 58.2% vs 44.9%; DMFS HR 0.71. First positive perioperative immunotherapy trial in HNSCC in >20 years"
        },
        "accessibility": {
          "score": 10,
          "rationale": "FDA approved June 13, 2025 for PD-L1 CPS>=1 resectable LA-HNSCC; patient has CPS 15 qualifying him for this regimen"
        },
        "safety_profile": {
          "score": 6,
          "rationale": "Grade 3+ AEs 44.6% vs 42.9% control; stomatitis 48%, radiation skin injury 40%, weight loss 36%; immune-mediated hepatitis 0.6% — liver steatosis requires monitoring for hepatic irAEs"
        },
        "biomarker_match": {
          "score": 9,
          "rationale": "PD-L1 CPS 15 exceeds the CPS>=1 threshold; CPS>=10 subgroup showed even stronger benefit (HR 0.66); patient is an ideal candidate"
        }
      },
      "mechanism_of_action": "Pembrolizumab is an anti-PD-1 monoclonal antibody that blocks the PD-1/PD-L1 checkpoint interaction, restoring T-cell-mediated antitumor immunity. Administered as 2 neoadjuvant cycles before surgery, then 15 adjuvant cycles with radiation +/- cisplatin. Neoadjuvant pembrolizumab primes systemic immune response while tumor is in situ.",
      "key_evidence": {
        "study_name": "KEYNOTE-689",
        "journal": "New England Journal of Medicine",
        "year": 2025,
        "sample_size": 714,
        "os_months": {
          "treatment": 51.8,
          "control": 30.4,
          "hazard_ratio": 0.7,
          "p_value": 0.0014
        },
        "pfs_months
... (truncated — read full file from experiment_reports\HN2-007_report.json)
```
